
Bioorganic and Medicinal Chemistry Letters p. 4080 - 4083 (2012)
Update date:2022-08-03
Topics:
Subasinghe, Nalin L.
Wall, Mark J.
Winters, Michael P.
Qin, Ning
Lubin, Mary Lou
Finley, Michael F.A.
Brandt, Michael R.
Neeper, Michael P.
Schneider, Craig R.
Colburn, Raymond W.
Flores, Christopher M.
Sui, Zhihua
Selective blockers of the N-type calcium channel have proven to be effective in animal models of chronic pain. However, even though intrathecally delivered synthetic ω-conotoxin MVIIA from Conus magnus (ziconotide [Prialt]) has been approved for the treatment of chronic pain in humans, its mode of delivery and narrow therapeutic window have limited its usefulness. Therefore, the identification of orally active, small-molecule N-type calcium channel blockers would represent a significant advancement in the treatment of chronic pain. A novel series of pyrazole-based N-type calcium channel blockers was identified by structural modification of a high-throughput screening hit and further optimized to improve potency and metabolic stability. In vivo efficacy in rat models of inflammatory and neuropathic pain was demonstrated by a representative compound from this series.
Wuxi Highness Chemical Co.,Ltd
website:https://www.phtpharmatech.com/
Contact:86-510-81771080
Address:No58 East Xinguan Rd, Guanlin Town, Yixing City, Jiangsu China
website:http://www.afinechem.com
Contact:+86-571-85134551
Address:No. 206 Zhen Hua Road, Hangzhou 310030, Zhejiang, China
Shanghai united Scientific Co.,Ltd.
Contact:+86-21-53535353
Address:28F No.900 huaihai Road Shanghai China
Hangzhou JINLAN Pharm-Drugs Technology Co., Ltd
website:http://www.jlpharms.com
Contact:86-571-86982636
Address:Rm A606, Fuyi Center, jianqiao street
Shanghai Taibao Pharmaceutical Technology Co., Ltd(expird)
Contact:021-52217366
Address:shanghai
Doi:10.1039/c0cc04348f
(2011)Doi:10.1016/j.bmcl.2015.07.023
(2015)Doi:10.1016/0040-4039(91)85090-R
(1991)Doi:10.1021/ja00167a070
(1990)Doi:10.1016/j.bmcl.2010.11.010
(2011)Doi:10.1021/ja111540g
(2011)